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Abstract
Objective To present data on the parentally-reported use of
all types of medicinal products in children from 0 to
7.5 years, in a large cohort in south-west England.
Methods Participants in the population-based Avon Longi-
tudinal Study of Parents and Children (ALSPAC) have been
sent self-completion postal questionnaires since they were
enrolled during pregnancy. The use of medicinal products
has been obtained from questionnaires sent out when the
study children were 4 weeks, 54, 78 and 91 months old.
Results The data included prescription, over-the-counter and
complementary and alternative medicines. Around three-
quarters of study children were exposed to some form of
medicinal product before 8 weeks of age. Dermatological
preparations were the most commonly used products in
young babies. Activated dimeticone, for treatment of colic
and flatulence, was given to 16% of babies and gripe water
was used by 13%. Other commonly reported products
included oral and topical antifungals and ophthalmic anti-
biotics. Several OTC products, not licensed for use in this
age group, were reported. At each of theolder ages surveyed,
over 95% of children had used some form of medicinal
product within the previous 12–18 months. Use of several
product categories was higher at 54 months than at 78 or
91 months, such as topical steroids, analgesics (mostly
paracetamol) and systemic antibiotics (mainly amoxicillin).
Conversely, use of other categories, such as asthma
medication, throat preparations (sprays and lozenges) and
anti-inflammatory products, increased with increasing age.
Conclusion Parentally-reported use of medicinal products
in the ALSPAC study children appears to be consistent with
data from other sources. The use of medicinal products by
young children is high and does not always conform to the
product labelling.
Keywords Children.Paediatricdruguse.Medication.
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Introduction
It is now well recognised that there is a need for more
studies to obtain paediatric information on medicines used
in children with the aim of reducing the amount of
unlicenced and off-label use of medicines in this popula-
tion. In 2002, 15% of children under 5 and 20% of children
aged 5–15 were reported as having a long-standing illness
[13]. In addition, young children may experience a range of
relatively minor ailments requiring medical treatment. A
previous report using data from this cohort showed that
cold, cough, high fever, colic/stomach ache, diarrhoea and
vomiting were very common symptoms in the pre-school
years, and that cough, cold, earache and high temperature
are the most common symptoms to present to medical
services [6]. In 2004, 35.7 million prescription items were
dispensed in the community for children under 16 at a cost
of £293.8 million [7]. This represents an average of 4.5
items per head in the age range 0–15 years [7]. The
categories of drugs most frequently prescribed for children
are antibacterials, analgesics and bronchodilators [12].
Prescribing outside the terms of the product licence occurs
in drugs commonly prescribed in general practice such as
systemic antibiotics [11].
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National Health Service prescription in the UK, parents
may also choose to purchase products over-the-counter
(OTC) for various reasons, such as convenience and
confusion over their entitlements [2]. In a US survey
involving 8,145 3-year-olds, 54% had been given an OTC
medication in the last 30 days, most commonly paracetamol
and cough/cold medicines [8], and a Norwegian study
concluded that paracetamol was an important tool for
parents in managing their children’si l l n e s s e s[ 9]. A
significant proportion of OTC medicines used in children
may be purchased from non-pharmacy outlets, where
advice on appropriate use is unavailable [3].
This study describes the patterns of parentally-reported
use of all types of medicinal products in a large community
sample of young children, at four data collection times
between the ages of 4 weeks and 7.5 years.
Methods
The data for this study were collected as part of the Avon
Longitudinal Study of Parents and Children (ALSPAC): a
longitudinal study designed to investigate the health and
development of children [5]. The study was approved by
the ALSPAC law and ethics committee, and the three local
research ethics committees.
Pregnant women resident in the three Bristol-based
health districts in the former county of Avon in southwest
England, and with an expected delivery date falling
between 1 April 1991 and 31 December 1992, were eligible
to be enrolled. The core ALSPAC sample consists of
14,212 women who had a total of 14,541 study pregnan-
cies, involving 14,676 fetuses, resulting in 14,062 live
births. An additional 548 children from 542 eligible
pregnancies not included in the core sample were included
in the study from age 7. Cohort retention has been good,
and we are currently in regular contact with approximately
11,000 families. Further details can be obtained from the
ALSPAC website, http://www.alspac.bris.ac.uk.
From various studies performed at the planning stage,
the Avon population was considered to be broadly similar
to that of the whole of Great Britain. After delivery, the
representative nature of the sample was assessed. As in
similar studies, the ALSPAC cohort has a slight shortfall in
the less affluent families and a shortfall in ethnic minority
mothers. Birth weights and lengths and growth measures in
ALSPAC are very similar to national standards [5].
The primary source of data collection is via postal
questionnaires about the health, development and home
environment of the study children completed by each
child’s main carer, usually the mother. This paper presents
data obtained from four such questionnaires administered
when the study children were 4 weeks, 54, 78 and
91 months old. Each of these asked questions, designed
by the ALSPAC study team, about the use of medicinal
products.
The 4-week questionnaire (sent out between 1991 and
1993), asked the baby’s mother to: “Please list all the
ointments, pills and medicines that have been given to your
baby while he/she has been at home. Check: have you
included ointments to prevent nappy rash, eyedrops, herbal
remedies, etc.”
The questionnaire sent out between 1995 and 1997,
when the child was 54 months of age (4.5 years) asked the
following:
1. Children often have accidents or illnesses that need
treatment. Please indicate which of the following have
been given to your child since he/she was 3 years old
a. Cough medicine
b. Antibiotics/penicillin
c. Throat medicine
d. Vitamins
e. Paracetamol/calpol
f. Ointment for skin
g. Eye ointment
h. Diarrhoea mixture/pills
i. Dimotapp/decongestant
j. Ear drops
k. Eye drops
l. Iron
m. Laxatives
n. Homeopathic medicine
o. Herbal medicine
p. Other
For each category, the carer was asked to tick
whether the response was ‘Never’, ‘Yes, for one
episode only’ or ‘Yes, for 2 or more episodes’; and ‘If
yes, please give full names of substances if you can’.
2. Are there any pills, ointments or medicines that he/she
has taken every day or nearly every day for the last
3 months? (Include vitamins, skin cream, inhaler,
laxatives as well as antibiotics, homeopathic and herbal
remedies, etc.) If yes, please describe.
At 78 months (6.5 years, data collection 1997–1999)
and 91 months (7.5 years, data collection 1998–2000) the
first question was expanded slightly as follows:
1. Children often have accidents or illnesses that need
treatment. Please indicate which of the following have
been given to your child in the last 12 months.
a. Cough medicine
b. Antibiotics/penicillin
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d. Vitamins
e. Paracetamol/calpol
f. Ointment for skin
g. Eye ointment
h. Diarrhoea mixture/pills
i. Dimotapp*/decongestant
j. Ear drops
k. Eye drops
l. Iron
m. Laxatives
n. Homeopathic medicine
o. Herbal medicine
p. Asthma medication
q. Vaporiser
r. Other
(*active ingredients: brompheniramine, phenylephrine
and phenylpropanolamine)
The tick box response options, the request for full name
of the product, and the second question were the same as at
54 months.
After a questionnaire was sent out, if a response was not
received within 3 weeks, a reminder letter was sent. If the
questionnaire had still not been received after a further
2 weeks, a second reminder letter was sent. Finally, if no
response had been received after 3 months, a member of the
study team either rang the mother or visited her home, and
encouraged or helped her to complete the questionnaire.
The date of completion is included on each questionnaire,
so whilst all returned questionnaires are added to the
database and included in the overall response rate, those
that were completed after a defined cut-off date can be
excluded from individual analyses.
Most of the self-completion responses on the question-
naires are self-coding—the ticked reply box contains a
printed number that can be directly keyed. However, the
actual names of medicinal products used (including
vitamins and supplements, herbal products, homeopathic
remedies, over-the-counter and prescription products) were
collected as free text responses.
An ALSPAC drug dictionary has been developed based
on the World Health Organisation (WHO) Drug Dictionary
(first quarter 2000 version, provided free of charge by the
Uppsala Monitoring Centre). The ALSPAC dictionary
assigns a Drug Name and Anatomical–Therapeutic–Chem-
ical (ATC) classification as described in the WHO Drug
Dictionary to an individual product. The latter classification
groups medications according to the organ or body system
on which they are designed to act and their chemical,
pharmacological and therapeutic properties. Some drugs
have several ATC codes as they can be used in different
preparations on different body systems. The ALSPAC
dictionary codes preparations, and thus a single ATC, has
been assigned to each product. In the few cases where more
than one ATC code would have been possible, a decision
was made as to the most likely use in this population.
Additional details about the WHO Drug Dictionary can be
found on the WHO website: http://www.whocc.no/atcddd/.
In cases where a category of medicinal product was
ticked as having been used but no further details were
provided, a non-specific code for that category has been
added to the database of text responses.
For the purposes of this report, all responses indicating
that a product in the defined category had been used have
been included, thus indicating ‘ever use’ of these categories
of medicinal products rather than taking into account
frequency of use.
Results
The response rate was good: Table 1 gives the number of
questionnaires mailed and returned at each age. The
majority of questionnaires were completed at or close to
the intended age. For example, 90% of the returned month
54 questionnaires had been completed by 55 months and
99% by 58 months, so all data from the 54–91 month
questionnaires have been included. However, as the
purpose of the question at 4 weeks was to ascertain what
medicinal products were used on the study children as very
young babies, a cut-off was applied so that only question-
naires completed before the child was 8 weeks old were
included. Using this criterion, at least one questionnaire
was completed for 12,525 study children and all 4 were
completed for 6,635 children.
For most of the defined categories, the number of tick
box responses not supported with a text response giving the
name of the product increased between the ages of 54 and
91 months (at 4 weeks, responses to the medication
question were all collected as free text).
The week 4 questionnaire was completed before the
child was 8 weeks of age in 10,897 cases (80% of those
sent, 88% of those returned). Around three-quarters of
study children were exposed to some form of medicinal
product before 8 weeks of age. At this age, dermatological
products were most commonly reported, mainly those for
treatment and protection against nappy rash, such as
‘Sudocrem’, a proprietary product containing zinc oxide
used in 29% of babies, and zinc and castor oil cream used
in 22%. Simeticone (activated dimeticone) in products for
treatment of colic and flatulence, such as ‘Infacol’, was
given to 16% of babies. Gripe water (terpeneless dill seed
oil and sodium bicarbonate) was used in 13% of the cohort.
Other commonly reported products included oral and
topical antifungals and ophthalmic antibiotics (mostly
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drops. Some were given herbal drinks (2.2%), homeopathic
products (1.2%) and a variety of topical complementary
and alternative medicine products, such as calendula and
camomile creams (3.3%).
Several OTC products not licensed for use in this age
group were reported. For example, inhalant decongestant
products not licensed for children under 3 months of age—
Snuffle-babe Vapour Rub (eucalyptus oil, menthol and
thyme oil), Karvol Decongestant Capsules for inhalation
(levomenthol with chlorobutanol, pine oils, terpineol and
thymol) and Vicks Vaporub (levomenthol, camphor, euca-
lyptus oil and turpentine oil)— were used in over 6% of the
cohort, and xylometazoline nasal spray was used on 0.6%.
Calpol (paracetamol), which is licensed from 2 months, was
given to over 1% when they were under 8 weeks old.
At the older ages, 54, 78 and 91 months, 9,728 (78% of
those mailed), 8,578 (78%) and 8,269 (73%) question-
naires were completed and returned, respectively. In these
latter questionnaires, relatively few children were reported
not to have used any medicinal products in the preceding
12–18 months. At 54 months (4.5 years), only 129 children
(1.3% of those returning the questionnaire) were not
reported as having used a medicinal product since the age
of 3. At 78 and 91 months, the figures were 339 (4.0%) and
329 (4.0%), respectively. Table 1 shows the number of
products reported per child at each age.
Table 2 shows the frequency of use of medicinal products,
by ATC code, at each data collection time. The data are
presented as the total number of drugs reported in an ATC
class per number of children in which any products within
thisclasswereused(i.e.morethanoneproductinaclassmay
have been reported per child). The pattern of use of different
categories of medicinal product varied with age. Usage of
several product categorieswas higher at 54 monthsthanat78
or 91 months. For example, at 54 months, 1,052 children
(10.2%) were reported to have used topical steroids (mostly
hydrocortisone) compared with 7.4% at 78 months and 4.9%
at 91 months. Paracetamol (as a single ingredient) was
recorded for 9,211 children (94.7%) at 54 months, 7,595
(88.5%) at 78 months and 7,247 (87.6%) at 91 months. In
addition, systemic antibiotics (mainly amoxicillin), laxatives
(mostly lactulose), treatments for diarrhoea (mainly rehydra-
tion salts), various cough and cold products, emollient and
protective skin preparations (mostly paraffin-based proprie-
tary products), topical antipruritics, antihistamines and local
anaesthetic products were all greater at 54 months than at the
older ages.Conversely, use of other categories, such as throat
preparations (sprays and lozenges), and anti-inflammatory
products, increased with increasing age. Use of ‘asthma’
medication (mainly salbutamol and beclomethasone) also
increased with increasing age; at 54 months, 6.8% of the
cohort reported use of anti-asthmatics, by 78 months this had
increased to 12.0% and to 14.2% at 91 months. Of the 1,174
children reported as having used asthma medication at
91 months, 1,038 (88%) had previously had a diagnosis of
‘asthma’ from a doctor and 907 (77%) reported having
asthma in the past 12 months.
Treatmentsforlesscommonconditionswerealsoreported
by this community sample. By 91 months, 6 children were
using insulin, 17 reported methylphenidate (for attention
deficithyperactivity disorder)and 2 reportedthyroidtherapy.
At 54 months, 28 children reported antiepileptic medication
but this had reduced to 15 children by 91 months.
Between 54 and 91 months, a very small number of
children were reported to have been given an OTC medicine,
whilsttheywereyoungerthantheagespecifiedonthePatient
Information Leaflet or Summary Product Characteristics, for
example, aspirin, ‘Dequadin’ lozenges (dequalinium chlo-
ride), ‘Night Nurse Liquid’ (paracetamol, pomethazine
hydrochloride, dextromethorphan hydrobromide) and ‘Dio-
calm’ (morphine hydrochloride and attapulgite).
Table 1 Total number of medicinal products recorded per child at
each age
4 weeks
(<8 weeks)
54 months 78 months 91 months
No. of
questionnaires
sent out
13,659 12,374 10,914 11,251
No. of completed
questionnaires
10,897
a 9,725 8,578 8,269
Total no. products recorded per child
0 2,573 129 339 410
1 3,029 557 1,010 1,139
2 2,594 1,400 1,746 1,911
3 1,502 2,020 1,715 1,759
4 687 1,834 1,370 1,317
5 320 1,382 1,001 771
6 130 939 590 451
7 39 578 346 227
8 13 352 179 133
9 10 205 139 77
10 103 51 43
11 74 33 32
12 49 24 12
13 30 13 7
14 25 6 7
15 16 10 6
16 19 1 9
17 10 1 32
18 1 2 5
19 0 0 2
20 2 1
21 1 0
22 0
23 1
aCompleted within 8 weeks of birth
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3–4.5 years
78 months
5.5–6.5 years
91 months
6.5–7.5 years
No. of questionnaires returned with data 10,897 9,725 8,578 8,269
ATC text
A Gastrointestinal preparations 4,470/3,416 6,733/4,188 4,747/3,130 4,262/2,973
A01 Stomatological preparations 691/649 114/94 57/46 35/30
A02 Antacids, drugs for peptic ulcer
and flatulence
3,422/2,690 31/27 25/23 15/13
A03 Antispasmodics, anticholinergics
and propulsives
29/29 13/12 13/11 9/9
A06 Laxatives 41/41 528/421 277/200 328/262
A07 Antidiarrhoeals, intestinal
anti-inflammatories and
anti-infectives
39/38 693/682 196/191 227/224
A11 Vitamins 247/247 5,169/3,567 3,143/2,121 3,748/2,692
A12 Mineral supplements 1/1 170/155 40/27 158/149
B Blood and blood forming organs 61/47 57/50 28/21 32/25
B03 Antianaemic preparations 46/32 48/41 28/21 31/24
C Cardiovascular system 13/11 6/5 8/7 4/3
D Dermatologicals 9,618/6,397 5,105/3,269 3,538/2,653 2,988/2,441
D Dermatologicals unspecified 25/24 1,015/1,010 915/907 1,376/1,373
D01 Antifungals for dermatological use 584/557 173/163 185/173 125/118
D02 Emollients and protectives 7,908/5,655 1,954/1,453 12,18/928 690/519
D04 Antipruritics, including antihistamines,
anaesthetics
6/6 158/151 91/89 59/57
D06 Antibiotics and chemotherapeutics, topical 98/95 169/161 154/142 107/99
D07 Corticosteroids, topical 125/121 1,358/1,052 790/631 507/408
D08 Antiseptics and disinfectants 843/785 246/223 161/154 114/110
D11 Other dermatological preparations 25/25 16/14 11/11 3/3
G Genito-urinary system and sex
hormones
1/1 17/15 18/16 9/8
H Systemic hormones, excl sex hormones 3/3 69/59 63/56 49/40
H01 Pituitary, hypothalamic hormones
and analogues
0 2/2 12/8 14/11
H02 Corticosteroids for systemic use 1/1 64/55 48/46 34/28
J General anti-infectives for systemic use 354/341 6,505/5,976 3,322/3,151 2,434/2,358
J01 Antibacterials for systemic use 346/335 6,498/5,973 3,309/3,146 2,419/2,349
L Antineoplastic and immunomodulating
agents
0 0 1/1 2/1
M Musculo-skeletal system 0 63/62 111/107 119/118
M01 Anti-inflammatory and antirheumatic
products
0 62/61 105/103 117/116
N Nervous system 163/159 9,561/9,184 7,857/7,620 7,400/7,261
N02 Analgesics 157/154 9,510/9,181 7,802/7,616 7,344/7,256
N03 Anti-epileptics 1/1 39/28 38/21 25/15
N06 Psychoanaleptics (antidepressants/
stimulants)
1/1 4/2 5/5 24/17
P Antiparasitics, insecticides and
repellents
0 87/80 90/84 58/54
P02 Anthelmintics 0 66/65 62/59 37/36
P03 Ectoparasiticides, scabicides, insecticides,
repellents
0 14/13 22/22 17/16
R Respiratory system 1,168/1,032 9,609/6,995 8,615/5,492 7,796/5,131
R01 Nasal preparations 468/456 705/655 437/391 403/382
R02 Throat preparations 0 471/471 514/511 649/646
Table 2 Frequency of use of medicinal products, by ATC code, at
each age. Total number of drugs reported in a class/number of children
in which this class of product was used (individual children may have
used more than one product in a class). ATC level 1 (in bold) includes
all reported cases. ATC level 2 is given where 10 or more children
reported a product in this category in at least one questionnaire
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The advantage of collecting data on children’s use of
medicinal products from their parents/carers, as opposed to
from medical records and prescription databases, is that the
former are in a position to know what was actually given to
their children, rather than what may have been prescribed
but not collected or taken by the child. In addition, the data
potentially includes medication obtained from all sources—
GP’s, pharmacies, supermarkets, CAM practitioners,
friends, relatives and neighbours. However, potential issues
include the accuracy of recall (especially over long periods
of 12–18 months, as used at the older ages in this study)
and parental knowledge and understanding about the
medicines given to their child.
These data were collected over the period 1991–2000.
Between 1994 and 1998, the annual number of children aged
5–15 years prescribed antibacterial drugs ranged from 322 to
402 per 1,000 [12]. This compares favourably with the
current study where the number reporting use of antibiotics
over the previous 12 months was 367 per 1,000 at 6.5 years
of age. At 7.5 years, the rate was lower at 284 per 1,000, but
these latter data reflect use of antibiotics between 1997 and
2000, when a substantial decline occurred in the prescribing
of antibiotics by general practitioners, in an effort to curb the
spread of antibiotic resistance [14]. Children under 5 are
known to be the greatest users of antibiotics [10, 12], and the
data from this study are consistent with this in that antibiotic
use reported at 4.5 years was considerably greater than at 6.5
and 7.5 years.
The number of children aged 5–15 years prescribed
bronchodilators over the period 1994–1998 ranged between
135 and 141 per 1,000 boys and 113–118 per 1,000 girls
[12]. The prevalence of treated asthma in the same age
group was 128–132 per 1,000 boys and 100–106 per 1,000
girls, and around 94% of these are prescribed bronchodi-
lators [12]. In this study, the reported use of all ‘asthma’
medication for boys and girls combined was 120 per 1,000
at 6.5 years and 142 per 1,000 at 7.5 years. Thus, the
figures from this study do not suggest a lack of recall.
Indeed, at 7.5 years, the reported use of asthma medication
is slightly higher than the national figures. However, as the
latter combine data over a 10-year age range (5–15 years)
any differences at individual ages may be masked.
Therefore, as the questionnaire data on use of prescribed
antibiotics and anti-asthmatics in this study is in the range
expected from prescription data, parentally-reported use of
non-prescription medication in this cohort is also likely to
be reasonably reliable.
The findings suggest that most children use some form
of medication from a very young age. Medicines available
over-the-counter were widely used, although it was not
possible to determine from these data whether they were
actually purchased over-the-counter or prescribed. The
reason for use was not collected, so it was also not
possible to assess to what extent products were appropri-
ately used. For example, paracetamol has been found to be
used by parents to calm and settle their children and aid
sleep [1, 9]. Some products were used in children younger
than the age for which they were licensed. It was not
possible to assess general adherence to information given in
the patient information leaflets or whether advice was
sought prior to using a product outside the specifications,
but parents of young children should be encouraged to
follow the labelling advice or seek advice from a health
professional.
The ALSPAC database provides a resource to investigate
the use of commonly used medications with later health and
Table 2 (continued)
ATC code <8 weeks 54 months
3–4.5 years
78 months
5.5–6.5 years
91 months
6.5–7.5 years
No. of questionnaires returned with data 10,897 9,725 8,578 8,269
ATC text
R03 Anti-asthmatics 0 1,178/658 2,422/1,029 1,920/1,174
R05 Cough and cold preparations 697/643 7,839/6,434 5,058/4,678 4,684/4,391
R06 Antihistamines for systemic use 3/3 216/186 184/163 140/127
S Sensory organs 1496/1411 2954/2213 1051/884 1090/861
S01 Ophthalmologicals 1,316/1,257 1,852/1,444 536/438 633/499
S02 Otologicals 3/3 737/728 426/416 405/403
S03 Ophthalmological and otological
preparations
177/177 365/314 89/84 52/49
V Various 855/705 1,082/745 955/705 1,139/796
V03 All other therapeutic products
(including CAM)
587/504 1,079/744 954/704 1,138/795
V07 All other non-therapeutic products
(eg baby toiletries)
295/214 0 1/1 0
194 Eur J Clin Pharmacol (2007) 63:189–195development; for example paracetamol, which is widely
used and may be associated with development of asthma
[4]. Future work may also examine differences in usage by
sex of the child and socio-economic status of the parents.
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